Featured Stories
Study Results: New PLGA Research Demonstrates the Power of Teamwork in Improving Outcomes for Kids with Brain Tumors
Children diagnosed with low-grade astrocytomas, the most common type of pediatric brain tumor, have close to 90 percent overall survival rates.…
Pediatric Brain Tumor Foundation and A Kids’ Brain Tumor Cure Join Forces to Change the Outcome for All Children with Brain Cancer
ASHEVILLE, N.C. and BOSTON -- The Pediatric Brain Tumor Foundation (PBTF) and A Kids’ Brain Tumor Cure (AKBTC, a/k/a PLGA Foundation) are merging…
Attainment of Functional and Social Independence in Adult Survivors of Pediatric CNS Tumors: A Report from the St Jude Lifetime Cohort Study
Beyond survival, achieving independence is a primary goal for adult survivors of pediatric CNS tumors. Researchers at St. Jude recently concluded a…
Clinical Trials and Expanded Access to Experimental Drugs/Devices Get a Boost from Recent Legislation
When you or a family member is diagnosed with a serious or life-threatening disease, you have choices to make about your treatment once standard…
Scientific and Clinical PLGA Progress: Indebted to the Founding PLGA Scientific Advisors
Changing the outcome for PLGA patients through cutting-edge scientific and clinical research has finally become a reality. Thanks, in large part,…
From the Perspective of a Pediatric Brain Tumor Patient
16 year old Sammi of Team Samantha has turned her brain tumor diagnosis at the age of 3 into an opportunity to help others. She recently spoke at…
Research
- May 2018: Critical Mechanisms of Gene Regulation in Medulloblastoma
- March 2017: SickKids of Toronto, Dr. Uri Tabori: – Novel universal classification of childhood low grade gliomas using clinico-pathological and molecular methods.
- June 2016: DNA Analysis of Paediatric Low-Grade Astrocytomas Identifies Tumour-Specific Signature in Pilocytic Astrycotomas
- June 2016: Johns Hopkins Medical Center – Dr. Eric Raabe, Dr. Charles Eberhart, Dr. Fausto Rodriguez: Using Human Neural Stem Cells to Create Genetically Accurate Models of PLGG, Developing PLGG Models Using Patient-Derived Tumor Tissue, Dual mTOR/NOTCH inhibition as a Therapeutic Strategy for PLGG
- November 2015: Long Term Clinical Implications of PLGG Molecular Subgroups
- September 2015: Genomic Analysis of Matched Primary and Progressive Recurrent PLGAs
